# A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients

> **NCT07671378** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 24 (estimated)

## Conditions studied

- CLL (Chronic Lymphocytic Leukemia)

## Interventions

- **DRUG:** Zanubrutinib and sonrotoclax

## Key facts

- **NCT ID:** NCT07671378
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07671378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07671378, "A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07671378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*